《新股表现》云顶新耀(01952.HK)暗盘高开18%报65元 曾高见80元
根据辉立交易平台显示,明天挂牌的云顶新耀(01952.HK)暗盘高开18%报65元获承接,最高见80元,现造73.05元,较上市价55元,高33%,成交401万股。
云顶新耀是一家生物制药公司,自2017年创立以来已打造一个由八款极具前景的临床阶段候选药物组成的产品组合,有关药物覆盖肿瘤、免疫学、心肾疾病及感染性疾病。是次上市共发售6,354.7万股,其中10%公开发售获逾634倍超购,已启动回拨机制占比增至50%,认购一手中签率仅2%;股份以招股范围(50-55元)上限定价,料集资净额约32.84亿元,主要用作集团四款支柱产品的进行中及计划临床试验、登记备案准备及有关商业化的其他步骤或活动提供资金、为其他候选药物进行中及计划临床试验、登记备案准备及潜在商业化提供资金、用於业务发展活动及扩展药品管线提供资金等。上市联席保荐人分别为高盛及美银证券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.